NORTH BILLERICA, Mass., May 16, 2022 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“the Company”) (NASDAQ: LNTH), an established leader and fully integrated provider committed to innovative imaging ...
Patient undergoing PET/CT Investigators zero in on which patients might benefit most from PSMA-PET-guided salvage radiation therapy for post-RP recurrent prostate cancer. Study findings presented at ...
PSMA PET/CT accurately detects recurrent prostate cancer in 67-year-old man. 18F-DCFPyL-PSMA PET/CT shows extensive, intensely PSMA-avid local recurrence in prostate (bottom row; solid arrow) in ...
NORTH BILLERICA, Mass.--(BUSINESS WIRE)-- Lantheus Holdings, Inc. (NASDAQ: LNTH) (Lantheus), the parent company of Lantheus Medical Imaging, Inc. and Progenics Pharmaceuticals, Inc., a global leader ...
New prostate cancer research shows that adding an interim scan during therapy can help guide a patient's treatment. Prostate-specific membrane antigen (PSMA) positron emission tomography (PET) imaging ...
Treating PSMA-positive patients with mHSPC with the radioligand 177Lu-PSMA-617 on top of standard of care reduces their risk for radiographic progression or death. In patients with PSMA-positive ...
Builds on existing collaboration between Curium and Lantheus for prostate cancer PSMA-targeted PET imaging Deep-learning platform for standardization of comprehensive reporting in Europe PARIS, July ...
A novel targeted radionuclide therapy has shown promising clinical activity and low toxicity in a group of heavily pretreated men with metastatic castration-resistant prostate cancer (mCRPC). The ...
After decades of research, scientists inch closer to FDA approval for PSMA-targeted treatments that show promise for patients with an advanced form of prostate cancer. In the fall of 2016, Dr. Mark ...
Two novel radiolabeled small molecules targeting prostate-specific membrane antigen have excellent potential for further development as diagnostic and therapeutic radiopharmaceuticals, according to ...
The novel radiopharmaceutical 18F-PSMA-1007 is both effective and readily available for detecting malignant prostate cancer lesions, according to research published in the April issue of The Journal ...
New prostate cancer research shows that adding an interim scan during therapy can help guide a patient's treatment. Prostate-specific membrane antigen (PSMA) positron emission tomography (PET) imaging ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results